ERBB2 and neoplasm: It was further reported that HER2 status evaluation, currently used in clinical practice might not reflect the potential benefit of anti-HER2 therapy, as single HER2-positive tumor cells were not sufficient to classify the tumor asHER2-positive [194,237].